AstraZeneca Gets CDSCO Panel Nod To study Baxdrostat Tablets and Dapagliflozin Tablets Dr. Divya Colin7 Feb 2025 6:00 PM ISTNew Delhi: AstraZeneca has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation...
AstraZeneca Gets CDSCO Panel Nod to Study anti-cancer drug Dato-DXd and Durvalumab Dr. Divya Colin5 Jan 2024 6:00 PM ISTNew Delhi: The drug major AstraZeneca has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
CDSCO Panel Grants AstraZeneca's Protocol Amendment Proposal for Anifrolumab Dr. Divya Colin4 Jan 2024 5:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation CDSO has approved the drug major's...
AstraZeneca Gets CDSCO Panel Nod to Study anticancer drug Volrustomig Dr. Divya Colin3 Jan 2024 6:00 PM ISTNew Delhi: The drug major AstraZeneca has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
CDSCO Panel grants AstraZeneca's Protocol Amendment Proposal for Sodium zirconium cyclosilicate Dr. Divya Colin31 Dec 2023 5:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the protocol...
Submit safety, efficacy data of Indian Patients: CDSCO Panel Tells AstraZeneca on additional indication of Enhertu 100mg Dr. Divya Colin29 Dec 2023 6:15 PM ISTNew Delhi: In response to the drug major AstraZeneca's proposal for the additional indication of Trastuzumab Deruxtecan Powder Concentrate Solution...
AstraZeneca Gets CDSCO Panel Nod for Enhertu 100mg for additional indication of breast cancer Dr. Divya Colin25 Dec 2023 6:00 PM ISTNew Delhi: Noting an unmet medical need in the country, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
SGLT2 inhibitors can lead to serious genital infection: USFDA warning Ruby Khatun Khatun31 Aug 2018 9:00 AM ISTThe SGLT2 inhibitors approved by the FDA include Johnson and Johnson's Invokana, Eli Lilly & Co's Jardiance, as well as those from Bristol-Myers...
